Literature DB >> 21705422

Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease.

Leonardo Cruz de Souza1, Fabian Corlier, Marie-Odile Habert, Olga Uspenskaya, Renaud Maroy, Foudil Lamari, Marie Chupin, Stéphane Lehéricy, Olivier Colliot, Valérie Hahn-Barma, Dalila Samri, Bruno Dubois, Michel Bottlaender, Marie Sarazin.   

Abstract

While the clinical presentation of posterior cortical atrophy is clearly distinct from typical Alzheimer's disease, neuropathological studies have suggested that most patients with posterior cortical atrophy have Alzheimer's disease with an atypical visual presentation. We analysed in vivo pathophysiological markers of Alzheimer's disease such as cerebrospinal fluid biomarkers and positron emission tomography imaging with ¹¹C-labelled Pittsburgh compound-B in posterior cortical atrophy to determine whether biochemical profile and fibrillar amyloid-β burden topography are associated with the clinical presentation. Nine patients with posterior cortical atrophy and nine with typical Alzheimer's disease individually matched for age, duration and severity of the disease and 10 cognitively normal age-matched controls were included. ¹¹C-labelled Pittsburgh compound-B images were analysed both using volumes of interest and on a voxel-wise basis using statistical parametric mapping, taking into account the individual regional cortical atrophy. Cerebrospinal fluid biomarkers did not differ between posterior cortical atrophy and patients with Alzheimer's disease. Compared with normal controls, both posterior cortical atrophy and Alzheimer's disease groups showed increased ¹¹C-labelled Pittsburgh compound-B uptake. No significant difference was found in regional or global ¹¹C-labelled Pittsburgh compound-B binding between posterior cortical atrophy and Alzheimer's disease groups with both volumes of interest and voxel-wise basis using statistical parametric mapping methods. Our findings demonstrate that cerebrospinal fluid biomarkers and positron emission tomography imaging with ¹¹C-labelled Pittsburgh compound-B may be useful in identifying an atypical visual form of Alzheimer's disease. The similar topography of fibrillar amyloid-β deposition between typical Alzheimer's disease and posterior cortical atrophy groups suggests that, although amyloid-β accumulation plays a critical role in the pathogenesis of Alzheimer's disease, other factors such as neurofibrillary tangles may contribute to the different clinical features observed in posterior cortical atrophy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705422     DOI: 10.1093/brain/awr130

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  51 in total

1.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

2.  Biparietal variant of Alzheimer's disease: a rare presentation of a common disease.

Authors:  Inês B Marques; Miguel Tábuas-Pereira; Miguel Milheiro; Isabel Santana
Journal:  BMJ Case Rep       Date:  2015-01-05

3.  Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease.

Authors:  William C Kreisl; Chul Hyoung Lyoo; Jeih-San Liow; Joseph Snow; Emily Page; Kimberly J Jenko; Cheryl L Morse; Sami S Zoghbi; Victor W Pike; R Scott Turner; Robert B Innis
Journal:  Neurobiol Aging       Date:  2016-12-16       Impact factor: 4.673

4.  Out of sight, out of mind: the case of a 62-year-old man with visual complaints and cognitive decline.

Authors:  Saurav Das; Adam S Fleisher; Roy Yaari; James D Seward; Anna D Burke; Helle Brand; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2014-02-27

5.  Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease.

Authors:  Edmond Teng; Tritia R Yamasaki; Michelle Tran; Julia J Hsiao; David L Sultzer; Mario F Mendez
Journal:  Dement Geriatr Cogn Disord       Date:  2013-12-31       Impact factor: 2.959

6.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

Review 7.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

8.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Authors:  Ming-Jang Chiu; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Ta-Fu Chen; Jen-Je Chieh; Hsin-Hsien Chen; Ting-Chi Chen; Chia-Shin Ho; Shuo-Fen Chang; Hao Chun Liu; Chin-Yih Hong; Hong-Chang Yang
Journal:  ACS Chem Neurosci       Date:  2013-10-23       Impact factor: 4.418

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Visual impairment and posterior cortical atrophy preceding rapid progressive dementia.

Authors:  Kai Ivar Müller; Svein Ivar Bekkelund
Journal:  BMJ Case Rep       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.